Innovation Pharmaceuticals Inc (IPIX)

[frrol]

Beth Israel (sister facility to DF) did the in vivo preclinical combo study of Kevetrin and sunitinib on renal cell carcinoma, so it makes sense that they would pursue this with them. The preclinical had good results. If DF or BI agrees and goes forward with it, that's a heartening sign that there is enthusiasm from the Phase 1 too.